NeOnc Technologies Announces August 12 Conference Call To Present Topline Phase 2a Results From NEO100-01 Trial Of Intranasal NEO100 In IDH1-Mutant Glioma

Loading news article.

NeOnc Technologies Announces August 12 Conference Call To Present Topline Phase 2a Results From NEO100-01 Trial Of Intranasal NEO100 In IDH1-Mutant Glioma | WAPE

NeOnc Technologies Announces August 12 Conference Call To Present Topline Phase 2a Results From NEO100-01 Trial Of Intranasal NEO100 In IDH1-Mutant Glioma

Article summary

Related companies

Comments —